{"id":14904,"date":"2024-11-25T18:10:33","date_gmt":"2024-11-25T10:10:33","guid":{"rendered":"https:\/\/flcube.com\/?p=14904"},"modified":"2024-11-25T18:10:35","modified_gmt":"2024-11-25T10:10:35","slug":"jiangsu-chia-tai-fenghais-als-treatment-fhnd1002-selected-for-cdes-patient-centered-care-plan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14904","title":{"rendered":"Jiangsu Chia Tai Fenghai&#8217;s ALS Treatment FHND1002 Selected for CDE&#8217;s Patient-Centered Care Plan"},"content":{"rendered":"\n<p>China\u2019s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)&#8217;s FHND1002 granules in the patient-centered rare disease drug development pilot program, known as the Care Plan. The official announcement is expected within the coming week.<\/p>\n\n\n\n<p><strong>FHND1002: Focusing on Patient Experience in ALS Research<\/strong><br>FHND1002, currently in the pre-Investigational New Drug (pre-IND) stage, is being prepared for a study that will focus on the patient experience of amyotrophic lateral sclerosis (ALS). The patient experience data collected will be utilized to explore the optimization of ALS efficacy indicators, ensuring that the drug development process is more closely aligned with the needs and experiences of those living with the disease. Additionally, digital health technology will be applied in the trials, and the implementation of decentralized clinical trials will be explored to enhance the efficiency and accessibility of the research process.<\/p>\n\n\n\n<p><strong>CDE&#8217;s Care Plan Aims to Enhance Rare Disease Drug Development<\/strong><br>The Care Plan program, officially launched by CDE in September, is designed to guide and assist research and development entities in fully incorporating patient perspectives throughout the drug development process. The program aims to enhance the scientific, standardized, and rational integration of patient experience data into the clinical research and development of rare disease drugs. This approach is expected to promote high-quality and efficient development and marketing of rare disease drugs. Since its inception, the Care Plan has included drugs such as Pfizer&#8217;s marstacimab, China Resources Double-Crane Pharmaceutical Co., Ltd\u2019s (SHA: 600062) hydroxocobalamine, and Sanofi Genzyme\u2019s fitusiran.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai&#8230;<\/p>\n","protected":false},"author":1,"featured_media":14907,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[102,2336,2337,24],"class_list":["post-14904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-cde","tag-chia-tai-fenghai-pharmaceutical","tag-ctfh","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Chia Tai Fenghai&#039;s ALS Treatment FHND1002 Selected for CDE&#039;s Patient-Centered Care Plan - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)&#039;s FHND1002 granules in the patient-centered rare disease drug development pilot program, known as the Care Plan. The official announcement is expected within the coming week.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14904\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Chia Tai Fenghai&#039;s ALS Treatment FHND1002 Selected for CDE&#039;s Patient-Centered Care Plan\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14904\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T10:10:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-25T10:10:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"718\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Chia Tai Fenghai&#8217;s ALS Treatment FHND1002 Selected for CDE&#8217;s Patient-Centered Care Plan\",\"datePublished\":\"2024-11-25T10:10:33+00:00\",\"dateModified\":\"2024-11-25T10:10:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c3db17a2ce532d8edbf7e35500dca1b3.png\",\"keywords\":[\"CDE\",\"Chia Tai Fenghai Pharmaceutical\",\"CTFH\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14904#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14904\",\"name\":\"Jiangsu Chia Tai Fenghai's ALS Treatment FHND1002 Selected for CDE's Patient-Centered Care Plan - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c3db17a2ce532d8edbf7e35500dca1b3.png\",\"datePublished\":\"2024-11-25T10:10:33+00:00\",\"dateModified\":\"2024-11-25T10:10:35+00:00\",\"description\":\"China\u2019s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)'s FHND1002 granules in the patient-centered rare disease drug development pilot program, known as the Care Plan. The official announcement is expected within the coming week.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14904\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c3db17a2ce532d8edbf7e35500dca1b3.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/c3db17a2ce532d8edbf7e35500dca1b3.png\",\"width\":1080,\"height\":718,\"caption\":\"Jiangsu Chia Tai Fenghai's ALS Treatment FHND1002 Selected for CDE's Patient-Centered Care Plan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14904#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Chia Tai Fenghai&#8217;s ALS Treatment FHND1002 Selected for CDE&#8217;s Patient-Centered Care Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Chia Tai Fenghai's ALS Treatment FHND1002 Selected for CDE's Patient-Centered Care Plan - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)'s FHND1002 granules in the patient-centered rare disease drug development pilot program, known as the Care Plan. The official announcement is expected within the coming week.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14904","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Chia Tai Fenghai's ALS Treatment FHND1002 Selected for CDE's Patient-Centered Care Plan","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14904","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-25T10:10:33+00:00","article_modified_time":"2024-11-25T10:10:35+00:00","og_image":[{"width":1080,"height":718,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14904#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14904"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Chia Tai Fenghai&#8217;s ALS Treatment FHND1002 Selected for CDE&#8217;s Patient-Centered Care Plan","datePublished":"2024-11-25T10:10:33+00:00","dateModified":"2024-11-25T10:10:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14904"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14904#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png","keywords":["CDE","Chia Tai Fenghai Pharmaceutical","CTFH","Rare \/ orphan disease drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14904#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14904","url":"https:\/\/flcube.com\/?p=14904","name":"Jiangsu Chia Tai Fenghai's ALS Treatment FHND1002 Selected for CDE's Patient-Centered Care Plan - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14904#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14904#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png","datePublished":"2024-11-25T10:10:33+00:00","dateModified":"2024-11-25T10:10:35+00:00","description":"China\u2019s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)'s FHND1002 granules in the patient-centered rare disease drug development pilot program, known as the Care Plan. The official announcement is expected within the coming week.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14904#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14904"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14904#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png","width":1080,"height":718,"caption":"Jiangsu Chia Tai Fenghai's ALS Treatment FHND1002 Selected for CDE's Patient-Centered Care Plan"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14904#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Chia Tai Fenghai&#8217;s ALS Treatment FHND1002 Selected for CDE&#8217;s Patient-Centered Care Plan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/c3db17a2ce532d8edbf7e35500dca1b3.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14904"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14904\/revisions"}],"predecessor-version":[{"id":14963,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14904\/revisions\/14963"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14907"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}